No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
455 |
4. Check minimum number of eventsNone |
455 |
5. Include endpointsNone |
455 |
6. Filter based on genotype QC (FinnGen only) |
436 |
Control definitions (FinnGen only)
- Control exclude
- H7_OCUMUSCLE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other specified and unspecified strabismus
based on the number of shared cases.
Similar with more cases:
- Other strabismus
- Strabismus
- Disorders of ocular muscles, binocular movement, accommodation and refraction
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4547 | 2406 | 2136 |
| Only index persons | 3496 | 1882 | 1614 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.07 | 0.06 |
| Only index persons | 0.07 | 0.07 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 9.45 | 11.12 | 7.46 |
| Only index persons | 16.21 | 20.13 | 11.64 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 436 | 279 | 157 |
| Unadjusted period prevalence (%) | 0.09 | 0.10 | 0.07 |
| Median age at first event (years) | 42.87 | 42.71 | 43.17 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 455
- Matched controls
- 4550
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H50.9
ICD-10 Finland
Strabismus, unspecified
1880.6
233.8
207
*
H50.8
ICD-10 Finland
Other specified strabismus
+∞
217.7
191
*
H53.2
ICD-10 Finland
Diplopia
26.2
116.0
84
39
H50.0
ICD-10 Finland
Convergent concomitant strabismus
822.3
73.3
70
*
H50.2
ICD-10 Finland
Vertical strabismus
403.3
69.6
68
*
37309
ICD-8 Finland
Strabismus, Unspecified
+∞
66.3
62
*
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
+∞
61.9
58
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
6.9
59.2
107
195
H50.31
ICD-10 Finland
Intermittent exotropia
+∞
52.1
49
*
H50.1
ICD-10 Finland
Divergent concomitant strabismus
+∞
51.0
48
*
CEC00
NOMESCO Finland
Recession of extraocular muscle
+∞
47.8
45
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.4
46.0
156
483
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
10.0
44.2
53
59
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
92.4
38.5
42
5
H50.30
ICD-10 Finland
Intermittent esotropy
+∞
31.6
30
*
H50.52
ICD-10 Finland
Exophoria
80.2
27.1
30
*
37300
ICD-8 Finland
Strabismus, Concomitans convergens
+∞
26.3
25
*
H03BB01
ATC
carbimazole; oral
6.4
24.8
43
73
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
7.4
24.1
36
52
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
7.5
23.6
35
50
CEW99
NOMESCO Finland
Other operation on extraocular muscle
+∞
23.1
22
*
CEC60
NOMESCO Finland
Transposition of extraocular muscle with adjustable suture
+∞
22.1
21
*
CA1BG
NOMESCO Finland
Eye and orbita MRI examination with high intensity magnet
84.4
21.9
24
*
H50.51
ICD-10 Finland
Esophoria
230.6
21.8
22
*
H062, E050,
ICD-10 Finland
+∞
21.0
20
*
H52.1
ICD-10 Finland
Myopia
8.8
20.3
26
31
XCK00
NOMESCO Finland
Perimetry
4.8
18.9
45
102
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
+∞
18.9
18
*
H50.6
ICD-10 Finland
Mechanical strabismus
+∞
17.8
17
*
H53.1
ICD-10 Finland
Subjective visual disturbances
3.9
16.9
52
144
H49.1
ICD-10 Finland
Fourth [trochlear] nerve palsy
+∞
16.8
16
*
H53.0
ICD-10 Finland
Amblyopia ex anopsia
29.8
15.3
20
7
CEC90
NOMESCO Finland
Total transposition of extraocular muscle or muscles
+∞
13.6
13
*
BAA60
NOMESCO Finland
Total thyroidectomy
5.3
12.8
26
51
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.1
12.6
56
196
Z3231
NOMESCO Finland
Registered nurse
2.2
12.4
147
823
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.1
12.0
150
856
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.0
11.5
186
1162
3503
FHL
Single muscle retroposition
+∞
11.5
11
*
37301
ICD-8 Finland
Strabismus, Concomitans divergens
+∞
11.5
11
*
ZXE10
NOMESCO Finland
More than one and less than three hours
2.0
11.4
171
1041
ZXA00
NOMESCO Finland
Right side
2.2
10.9
121
656
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
22.1
10.7
15
7
H52.0
ICD-10 Finland
Hypermetropia
10.4
10.6
20
20
H06.2
ICD-10 Finland
Dysthyroid exophthalmos
112.5
10.5
11
*
F95
ICPC
Strabismus
112.5
10.5
11
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.8
10.4
57
224
H02.4
ICD-10 Finland
Ptosis of eyelid
5.5
10.2
20
38
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
3.5
9.6
34
103
N03AX14
ATC
levetiracetam; systemic
5.0
9.6
21
44
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
9.6
130
754
CAC30
NOMESCO Finland
Decompression of orbit to sinuses
+∞
9.4
9
*
CEC30
NOMESCO Finland
Resection of extraocular muscle
+∞
9.4
9
*
H51.1
ICD-10 Finland
Convergence insufficiency and excess
+∞
9.4
9
*
AA1AD
NOMESCO Finland
CT of head and brain
2.1
9.3
109
599
L04AX01
ATC
azathioprine; systemic
4.1
9.2
25
63
H52.3
ICD-10 Finland
Anisometropia and aniseikonia
24.6
8.9
12
5
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
3.4
8.9
33
103
ZXD20
NOMESCO Finland
Day surgery
2.4
8.8
67
308
ZXD10
NOMESCO Finland
Scheduled procedure
1.8
8.5
171
1124
H03AA01
ATC
levothyroxine sodium; systemic
2.0
8.5
111
634
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
+∞
8.4
8
*
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
+∞
8.4
8
*
E89.01
ICD-10 Finland
Postsurgical hypothyroidism
6.7
8.3
20
31
ZX120
NOMESCO Finland
Intravenous
2.6
8.3
51
213
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
14.8
8.2
13
9
XCD10
NOMESCO Finland
Electrophysiological examination of eye
4.9
8.2
18
38
H05.2
ICD-10 Finland
Exophthalmic conditions
34.0
8.1
10
*
H02AB06
ATC
prednisolone; systemic
1.8
7.8
204
1439
WX402
NOMESCO Finland
General anaesthesia
2.0
7.7
102
582
ZXA05
NOMESCO Finland
Left side
2.0
7.6
103
593
WX002
NOMESCO Finland
Sedation and analgesia
2.0
7.5
85
460
CAC44
NOMESCO Finland
Combined decompression of orbit
81.4
7.4
8
*
37303
ICD-8 Finland
Strabismus, Heterophoria (exophoria, esophroria, hypophoria)
+∞
7.3
7
*
CA1BM
NOMESCO Finland
Eye and orbita MRI examination with 3 Tesla magnet
+∞
7.3
7
*
CA1CM
NOMESCO Finland
Eye and orbita extensive MRI examination with 3 Tesla magnet
30.5
7.2
9
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.2
7.0
60
291
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
2.5
6.9
44
186
ZXE20
NOMESCO Finland
More than three and less than five hours
2.1
6.8
65
328
Z3229
NOMESCO Finland
Other healthcare associate professional
2.4
6.6
45
197
R4110
NOMESCO Finland
Physiotherapy
1.8
6.5
120
760
CE2W4
NOMESCO Finland
Eye movement mapping
70.8
6.4
7
*
N03AX12
ATC
[U] gabapentin; oral
2.0
6.4
73
395
WX140
NOMESCO Finland
Parabulbar anesthesy
3.4
6.4
23
71
3504
FHL
Retroposition of two muscles
+∞
6.3
6
*
3780A
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Convergent concomitant strabismus[STRABISMUS CONCOMITANS CONVERGENS]
+∞
6.3
6
*
H50.59
ICD-10 Finland
Heterophor UNS
+∞
6.3
6
*
3780B
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Convergent concomitant strabismus[STRABISMUS CONVERGENS ALTERNANS]
+∞
6.3
6
*
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
5.2
6.2
18
36
ZXE00
NOMESCO Finland
One hour or less
1.7
6.1
175
1246
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
12.7
6.1
10
8
ZX090
NOMESCO Finland
Other technic of radiotherapy
4.0
6.0
17
44
R42
ICD-10 Finland
Dizziness and giddiness
1.9
6.0
90
533
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
47
97
5.29
22.06
3.7
1.8
6.24
6.28
iu/l
0.01
28
35
230
1648
1.80
8.62
7.6
6.4
1.22
1.22
mmol/l
0.28
201
1420
148
938
1.86
8.22
2.5
2.1
201.01
186.89
u/l
0.09
134
887
186
1270
1.79
8.06
2.1
1.8
93.51
95.43
pmol/l
0.19
109
634
208
1497
1.72
7.29
7.2
6.2
1.22
1.22
mmol/l
0.11
201
1375
169
1214
1.62
5.59
3.8
3.0
—
—
—
0
0
198
1481
1.60
5.53
3.0
2.3
71.27
75.31
nmol/l
1.35
182
1350
47
228
2.18
5.46
4.5
3.3
4.26
4.61
pmol/l
1.57
47
204
338
2880
1.68
5.40
5.5
3.9
14.85
14.61
pmol/l
1.00
330
2649
185
1373
1.59
5.27
6.9
4.5
35.82
36.44
g/l
0.74
180
1296
188
1409
1.57
5.09
14.1
10.9
1.12
1.19
inr
0.84
59
427
262
2137
1.53
4.71
12.4
9.2
3.92
3.95
e9/l
0.08
234
1884
248
2005
1.52
4.61
5.8
4.7
6.29
6.48
mmol/l
1.05
239
1847
136
964
1.59
4.60
3.4
3.0
0.29
0.38
e6/l
0.43
106
719
13
27
4.92
4.53
1.2
1.0
—
—
—
0
0
146
1057
1.56
4.49
3.9
3.0
143.31
111.94
e6/l
0.11
116
807
409
3740
1.93
4.36
17.0
11.8
23.54
21.50
mg/l
0.53
324
2854
7
6
11.82
4.29
1.0
1.0
—
—
—
0
0
14
41
3.49
4.21
1.1
1.0
—
—
—
0
0
223
1799
1.47
3.97
8.4
6.0
55.73
55.49
%
0.11
213
1711
21
84
2.57
3.77
1.9
2.4
24.85
6.54
e6/l
0.50
13
67
21
84
2.57
3.77
1.9
2.5
9708.64
344.87
e6/l
0.51
14
70
218
1766
1.45
3.72
6.3
6.1
12.17
11.81
umol/l
0.11
203
1671
309
2675
1.48
3.72
8.7
6.8
81.11
80.36
u/l
0.08
298
2514
400
3673
1.74
3.65
18.3
13.3
139.80
139.66
mmol/l
0.60
394
3580
14
40
3.58
3.63
1.1
1.1
—
—
—
0
0
401
3686
1.74
3.63
18.4
13.3
3.93
3.96
mmol/l
1.02
393
3584
54
319
1.79
3.61
8.6
7.6
1.05
1.01
mmol/l
0.02
46
258
311
2707
1.47
3.55
4.5
3.8
10.57
10.57
mm/h
0.00
300
2498
223
1831
1.43
3.46
8.6
6.2
29.39
29.94
%
0.32
215
1744
149
1137
1.46
3.42
4.1
2.9
2.35
2.36
mmol/l
0.60
137
1017
116
850
1.49
3.25
2.9
2.3
2.86
3.14
mg/l
0.70
100
730
208
1701
1.41
3.23
3.6
2.7
130.03
99.28
ug/l
0.73
191
1582
80
547
1.56
3.08
3.7
2.9
3.98
2.32
e6/l
0.52
50
298
8
16
5.07
3.06
2.6
1.4
—
—
—
0
0
12
36
3.40
3.04
1.2
1.1
—
—
—
0
0
137
1051
1.43
3.00
2.8
2.4
50.41
60.49
u/l
1.33
129
973
39
222
1.83
2.96
2.2
1.6
—
—
—
0
0
373
3411
1.52
2.96
6.3
4.6
1.87
2.22
mu/l
0.49
366
3169
8
17
4.77
2.93
3.6
4.1
0.81
1.37
ug/l
—
8
17
22
102
2.22
2.92
1.9
1.4
299.36
300.09
ug/g
0.00
12
60
36
201
1.86
2.91
1.6
1.5
31.00
22.84
iu/l
0.51
29
164
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
18
77
2.39
2.85
4.4
4.4
0.38
0.36
u/ml
—
9
42
12
39
3.13
2.79
1.3
1.2
—
—
—
0
0
90
648
1.48
2.72
1.5
1.6
428.23
12050800.48
pmol/l
0.50
83
556
42
253
1.73
2.66
1.4
2.7
68.64
70.36
ml/min/173m2
0.09
11
105
74
515
1.52
2.63
1.7
1.6
1234.34
1227.97
nmol/l
0.02
61
391
108
811
1.43
2.63
2.6
3.4
1467.95
912.14
ng/l
0.35
94
685
81
575
1.50
2.63
2.8
2.7
1.44
0.92
e6/l
0.54
50
321
7
15
4.72
2.60
1.9
1.1
—
—
—
0
0
9
25
3.65
2.58
2.0
1.9
—
—
—
0
0
18
82
2.24
2.50
2.2
1.6
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
22
3.68
2.37
1.9
1.1
—
—
—
0
0
8
22
3.68
2.37
4.3
2.9
29.39
28.68
umol/l
—
8
22
209
1772
1.33
2.37
3.8
3.3
0.00
0.00
estimate
-0.00
49
373
119
925
1.39
2.37
4.4
3.5
0.00
0.01
estimate
0.80
48
349
44
283
1.61
2.21
7.3
8.5
1.20
1.39
mmol/l
0.81
44
275
193
1633
1.32
2.17
2.9
2.5
—
—
—
0
0
41
263
1.61
2.09
7.5
9.3
24.74
24.73
mmol/l
0.01
41
263
146
1194
1.33
2.07
3.0
3.1
46.74
30.80
u/l
0.76
140
1138
128
1028
1.34
2.05
4.0
3.4
8.42
7.92
mmol/l
0.43
109
890
344
3173
1.34
1.98
5.6
5.1
38.80
39.00
mmol/mol
0.16
334
2985
209
1804
1.29
1.98
3.8
3.3
0.00
0.01
estimate
0.50
48
340
207
1789
1.29
1.92
5.1
4.5
0.00
0.00
estimate
0.50
47
356
356
3309
1.35
1.88
15.4
10.8
85.67
86.84
ml/min/173m2
0.42
284
2651
6
17
3.56
1.84
1.2
1.5
—
—
—
0
0
6
17
3.56
1.84
1.2
1.5
—
—
—
0
0
76
571
1.40
1.84
3.1
2.6
2.42
2.44
mmol/l
0.69
68
500
100
789
1.34
1.79
1.9
2.1
2.00
1.42
mg/l
0.22
70
590
94
739
1.34
1.72
1.6
1.5
19.51
21.48
nmol/l
0.71
87
631
142
1191
1.28
1.62
3.8
3.5
21.81
34.18
ng/l
1.27
91
752
103
829
1.31
1.61
2.9
2.3
—
—
—
0
0
273
2475
1.26
1.60
3.0
3.0
42.47
41.00
u/l
0.14
259
2349
6
20
3.03
1.58
1.0
1.2
1.81
1.65
mmol/l
—
6
20
28
177
1.62
1.55
1.7
1.6
—
—
—
0
0
8
33
2.45
1.54
1.0
1.0
—
—
—
0
0
434
4209
1.67
1.52
25.4
17.6
256.22
256.56
e9/l
0.04
427
4109
434
4211
1.66
1.49
25.6
17.8
40.00
40.41
%
0.68
412
3993
7
28
2.52
1.45
1.1
1.2
106.27
192.09
pmol/l
—
7
28
434
4214
1.65
1.44
25.4
17.6
4.53
4.54
e12/l
0.12
425
4104
96
786
1.28
1.32
3.7
3.2
1.02
1.02
kg/l
0.40
15
104
27
178
1.55
1.29
4.7
2.2
1.30
0.12
e6/l
0.51
27
170
18
107
1.71
1.27
1.5
1.4
0.00
0.07
iu/ml
—
5
22
26
171
1.55
1.26
1.4
1.3
—
—
—
0
0
9
45
2.02
1.24
2.4
2.2
—
—
—
0
0
5
19
2.65
1.22
2.6
1.3
—
—
—
0
0
73
586
1.29
1.17
3.4
3.5
44.35
291.52
ng/l
3.60
51
422
108
910
1.24
1.17
3.8
3.8
18.98
10.15
mg/mmol
0.38
71
571
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
20
2.52
1.15
1.4
1.9
111.40
114.00
%
—
5
20
57
444
1.32
1.14
2.9
2.1
2.37
2.43
g/l
0.26
52
408
406
3917
1.34
1.14
12.4
9.3
26.92
26.09
u/l
0.23
398
3790
79
645
1.27
1.12
1.3
1.3
44.91
33.63
iu/ml
0.18
17
205
12
67
1.81
1.05
1.1
1.2
—
—
—
0
0
12
67
1.81
1.05
1.1
1.2
—
—
—
0
0
154
1361
1.20
1.04
4.2
3.3
—
—
—
0
0
5
22
2.29
1.03
3.0
2.3
—
—
—
0
0
22
147
1.52
1.02
2.2
1.7
—
—
—
0
0
45
346
1.33
1.00
5.0
5.7
6.24
5.72
kpa
1.48
45
337
5
23
2.19
0.98
1.2
1.3
—
—
—
0
0
5
23
2.19
0.98
1.4
2.9
107.80
92.39
%
—
5
23
17
108
1.60
0.98
1.1
1.2
0.66
4.10
u/ml
—
9
67
33
242
1.39
0.98
2.0
2.3
14.06
7.36
ug/l
0.43
28
217
75
624
1.24
0.92
1.2
1.3
31.61
9.76
u/ml
0.38
24
250
113
982
1.20
0.91
1.3
1.4
0.88
2.12
u/ml
2.01
35
247
97
831
1.21
0.90
2.4
2.7
327.46
5125.52
umol/l
2.92
90
734
354
3389
1.20
0.87
4.4
4.0
5.88
5.83
mmol/l
0.25
338
3126
45
356
1.29
0.84
6.2
6.5
—
—
—
0
0
6
32
1.89
0.82
2.2
1.1
—
—
—
0
0
40
313
1.30
0.81
4.5
3.0
—
—
—
0
0
6
33
1.83
0.79
1.5
1.2
—
—
—
0
0
6
33
1.83
0.79
2.2
1.1
—
—
—
0
0
11
66
1.68
0.79
1.3
1.2
13.21
3.21
ug/l
0.50
11
57
48
387
1.27
0.78
2.7
3.0
6.82
7.00
umol/l
0.05
40
333
41
330
1.27
0.69
2.2
2.2
32.00
31.24
u/l
0.03
36
279
10
61
1.65
0.69
1.4
1.2
10.60
2.65
u/ml
—
5
23
5
27
1.86
0.68
2.8
1.6
—
—
—
0
0
5
27
1.86
0.68
4.2
3.5
—
—
—
0
0
18
246
0.72
0.65
1.3
1.5
—
—
—
0
0
8
130
0.61
0.64
1.1
1.4
—
—
—
0
0
8
130
0.61
0.64
1.1
1.4
—
—
—
0
0
8
130
0.61
0.64
1.1
1.4
—
—
—
0
0
32
401
0.78
0.64
3.7
3.9
28.44
31.94
%
1.61
27
278
10
63
1.60
0.62
1.3
1.2
5.60
3.66
u/ml
—
5
32
345
3329
1.15
0.62
3.6
3.6
1.32
1.27
mmol/l
0.53
331
3095
5
30
1.67
0.61
1.2
1.1
—
—
—
0
0
8
51
1.58
0.60
3.0
5.0
—
738.60
u/ml
—
0
5
14
97
1.46
0.59
1.1
1.2
—
—
—
0
0
0
23
0.00
0.58
0.0
5.3
—
37.60
—
0
5
10
65
1.55
0.56
1.1
1.3
—
—
—
0
0
6
38
1.59
0.54
1.0
1.1
—
—
—
0
0
9
61
1.48
0.54
1.0
1.1
—
—
—
0
0
13
91
1.44
0.53
1.6
2.7
—
—
—
0
0
13
91
1.44
0.53
1.1
1.4
—
—
—
0
0
16
117
1.38
0.53
1.5
1.3
—
—
—
0
0
59
513
1.17
0.50
1.9
1.8
—
—
—
0
0
357
3472
1.13
0.48
4.0
4.0
4.63
4.69
mmol/l
0.51
344
3253
362
3525
1.13
0.47
4.6
4.4
2.73
2.80
mmol/l
0.70
350
3274
56
639
0.86
0.47
2.3
2.3
—
—
—
0
0
15
112
1.35
0.45
1.5
2.0
—
—
—
0
0
16
121
1.33
0.45
1.2
1.1
—
—
—
0
0
16
121
1.33
0.45
1.2
1.1
—
—
—
0
0
9
130
0.69
0.43
1.1
1.4
—
—
—
0
0
10
139
0.71
0.42
1.1
1.5
—
—
—
0
0
13
96
1.36
0.42
2.1
2.3
2.35
2.86
g/l
1.97
13
88
32
379
0.83
0.42
1.4
1.6
—
—
—
0
0
11
79
1.40
0.41
1.9
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
41
355
1.17
0.38
1.7
1.7
—
—
—
0
0
5
36
1.39
0.38
1.4
3.5
—
—
—
0
0
9
67
1.35
0.38
1.4
1.5
15.92
20.07
u/l
—
9
54
9
68
1.33
0.38
4.8
2.9
60.67
56.97
%
—
9
68
10
72
1.40
0.37
1.3
1.3
—
43.93
—
0
7
12
90
1.34
0.36
1.1
1.4
411.57
213.00
u/ml
—
7
46
15
117
1.29
0.35
1.8
1.7
—
240.00
—
0
5
13
167
0.77
0.35
2.1
1.6
—
—
—
0
0
6
45
1.34
0.34
1.8
1.4
—
—
—
0
0
6
45
1.34
0.34
1.8
1.4
—
—
—
0
0
6
45
1.34
0.34
1.8
1.4
—
—
—
0
0
6
46
1.31
0.33
1.8
1.4
—
—
—
0
0
6
46
1.31
0.33
1.8
1.4
—
—
—
0
0
6
46
1.31
0.33
1.8
1.4
—
—
—
0
0
21
252
0.83
0.33
1.3
1.3
—
—
—
0
0
16
128
1.26
0.32
1.4
1.3
—
—
—
0
0
53
588
0.89
0.32
2.2
2.2
—
—
—
0
0
17
138
1.24
0.31
2.1
1.6
6.41
9.64
u/l
—
10
107
24
203
1.19
0.30
3.3
2.2
9793.80
3548.62
u/l
—
7
76
10
75
1.34
0.30
1.9
1.3
—
—
—
0
0
351
3448
1.08
0.26
3.9
4.0
1.44
1.48
mmol/l
1.17
338
3211
40
359
1.13
0.25
1.7
1.7
—
—
—
0
0
13
105
1.25
0.25
2.1
2.2
7.41
7.28
g/l
0.07
13
97
13
105
1.25
0.25
2.1
2.2
5.22
3.57
g/l
0.43
13
97
13
105
1.25
0.25
2.1
2.2
—
—
—
0
0
11
87
1.27
0.24
1.4
1.4
—
—
—
0
0
9
77
1.17
0.24
1.2
1.2
—
—
—
0
0
6
83
0.72
0.24
1.3
1.7
—
—
—
0
0
11
88
1.26
0.22
2.3
2.6
2.71
0.86
g/l
0.30
11
79
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
3.4
—
—
—
0
0
0
11
0.00
0.21
0.0
3.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
8
105
0.76
0.21
1.7
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
2.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
6
49
1.23
0.20
1.0
1.3
—
—
—
0
0
64
599
1.08
0.19
5.0
4.2
21.84
21.12
%
0.13
27
253
6
52
1.16
0.19
1.2
1.3
7.49
7.61
mmol/l
—
6
41
28
307
0.91
0.15
1.3
1.3
206.20
152.19
iu/ml
—
9
132
9
78
1.16
0.15
1.1
2.1
—
—
—
0
0
22
242
0.90
0.13
1.1
1.0
—
—
—
0
0
13
113
1.15
0.13
1.8
1.8
—
—
—
0
0
284
2799
1.04
0.13
3.4
3.4
—
—
—
0
0
16
142
1.13
0.13
1.4
1.3
171.23
277.17
miu/ml
—
8
73
14
123
1.14
0.12
2.1
2.0
—
—
—
0
0
70
673
1.05
0.10
1.6
1.5
—
—
—
0
0
5
44
1.14
0.10
1.4
1.3
—
—
—
0
0
5
45
1.11
0.10
1.2
1.6
—
—
—
0
0
11
97
1.14
0.09
1.5
2.2
9.98
10.44
g/l
0.18
11
88
29
273
1.07
0.08
7.0
4.4
0.85
1.47
mmol/l
0.44
23
191
5
63
0.79
0.08
1.6
1.7
—
—
—
0
0
5
63
0.79
0.08
1.6
1.7
—
—
—
0
0
5
65
0.77
0.08
1.4
1.8
—
—
—
0
0
32
303
1.06
0.08
2.0
1.8
—
—
—
0
0
6
75
0.80
0.07
1.0
1.3
—
—
—
0
0
46
442
1.05
0.07
3.0
2.8
0.59
0.70
ug/l
0.49
28
267
9
84
1.07
0.07
1.6
2.3
38.38
39.22
g/l
—
9
76
15
138
1.09
0.06
2.4
1.3
1.29
1.18
g/l
0.65
15
132
30
289
1.04
0.04
3.9
4.4
5.21
6.61
ug/l
0.17
22
248
13
121
1.08
0.03
1.2
1.2
—
—
—
0
0
95
963
0.98
0.03
1.7
1.7
—
—
—
0
0
94
928
1.02
0.03
1.6
1.6
1.29
1.38
mmol/l
0.69
86
799
11
118
0.93
0.03
1.7
1.6
—
—
—
0
0
14
132
1.06
0.02
1.7
1.5
—
—
—
0
0
14
147
0.95
0.01
2.7
1.5
—
—
—
0
0
17
163
1.04
0.01
8.5
4.9
9.36
9.09
kpa
0.23
17
157
39
384
1.02
0.00
2.0
1.9
—
—
—
0
0
12
124
0.97
0.00
1.7
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
3.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
6
62
0.97
-0.00
5.5
3.3
20.00
30.01
u/ml
—
6
62
8
88
0.91
-0.00
1.5
1.7
—
—
—
0
0
7
76
0.92
-0.00
2.3
1.7
191.71
237.61
pmol/l
—
7
71
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
1.55
—
0
6
9
89
1.01
-0.00
1.6
1.5
—
—
—
0
0
8
84
0.95
-0.00
1.1
1.3
—
—
—
0
0
8
79
1.01
-0.00
1.5
1.3
—
1.04
—
0
5
9
94
0.96
-0.00
1.1
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
63
0.95
-0.00
1.2
1.6
—
—
—
0
0
7
74
0.95
-0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.0
—
—
—
0
0
5
55
0.91
-0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
59
0.85
-0.00
1.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_STRABNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_STRABNAS | 1.175 [0.87, 1.58] | 0.284 |
| Birth year | 0.994 [0.99, 1.0] | 0.171 |
During the follow-up period (1.1.1998 — 31.12.2019), 80 out of 1777 females with H7_STRABNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_STRABNAS | 1.232 [0.89, 1.7] | 0.202 |
| Birth year | 0.987 [0.98, 1.0] | 0.016 |
During the follow-up period (1.1.1998 — 31.12.2019), 75 out of 1539 males with H7_STRABNAS died.
Mortality risk
Mortality risk for people of age
years, who have H7_STRABNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.091% | 0.215% |
| 5 | 0.655% | 1.266% |
| 10 | 1.807% | 3.642% |
| 15 | 3.292% | 7.24% |
| 20 | 5.626% | 11.799% |
Relationships between endpoints
↥Index endpoint: H7_STRABNAS – Other specified and unspecified strabismus
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data